{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:03:03Z","timestamp":1777356183551,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.1016\/s0168-8278(99)80061-0","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T16:48:51Z","timestamp":1027615731000},"page":"192-198","source":"Crossref","is-referenced-by-count":55,"title":["Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT"],"prefix":"10.1016","volume":"30","author":[{"given":"Johannes T.","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert G.M.","family":"Niesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solko W.","family":"Schalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0168-8278(99)80061-0_BIB1","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1002\/hep.510260701","article-title":"National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C.","volume":"26","author":"Anonymous","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0168-8278(97)80337-6","article-title":"A French consensus conference on hepatitis C: screening and treatment","volume":"27","author":"Dhumeaux","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB3","first-page":"700","article-title":"Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group","volume":"22","author":"Chemello","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0168-8278(95)80052-2","article-title":"Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group","volume":"23","author":"Lin","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group","volume":"332","author":"Poynard","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB6","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.1002\/hep.510260721","article-title":"Factors predictive of a beneficial response to therapy of hepatitis C.","volume":"26","author":"Davis","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/hep.510260637","article-title":"Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison","volume":"26","author":"Tong","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/AAC.37.3.595","article-title":"Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon","volume":"37","author":"Kleter","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0168-8278(98)80342-5","article-title":"Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients","volume":"28","author":"Brouwer","year":"1998","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/S0168-8278(99)80061-0_BIB10","first-page":"S17","article-title":"What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon","volume":"21","author":"Brouwer","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/JCM.32.2.306-310.1994","article-title":"Sequence analysis of the 5\u2032 untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands","volume":"32","author":"Kleter","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB12","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1002\/hep.510260713","article-title":"Therapy of hepatitis C: overview","volume":"26","author":"Lindsay","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0168-8278(97)80103-1","article-title":"Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres","volume":"26","author":"Schalm","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"double-blind, placebo-controlled trial of interferon alpha- 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1053\/gast.1997.v113.pm9352868","article-title":"Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.","volume":"113","author":"Gavier","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.510270433","article-title":"Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa","volume":"27","author":"Zeuzem","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.510260131","article-title":"Measuring hepatitis C viremia in clinical samples: can we trust the assays?","volume":"26","author":"Pawlotsky","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0166-0934(96)02011-3","article-title":"International collaborative study on the second EUROHEP HCV-RNA reference panel","volume":"58","author":"Damen","year":"1996","journal-title":"J Virol Methods"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/BF01316789","article-title":"Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study","volume":"38","author":"Iino","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S0168-8278(99)80061-0_BIB22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0168-8278(98)80343-7","article-title":"Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy","volume":"28","author":"Bekkering","year":"1998","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827899800610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827899800610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T05:12:32Z","timestamp":1578805952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827899800610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["S0168827899800610"],"URL":"https:\/\/doi.org\/10.1016\/s0168-8278(99)80061-0","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}